SCHEMBL4327653

SCHEMBL4327653

COc1cc(C2C(C#N)=C(N)Oc3c2ccc2ccccc32)cc2c1OCO2

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYB P10242 16/20 0.75
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
ALDH1A1 P00352 1/20 0.68
PKM P14618 1/20 0.68
HSD17B10 Q99714 1/20 0.68
MITF O75030 1/20 0.66
LMNA P02545 1/20 0.66
TUBB4A P04350 1/20 0.66
TP53 P04637 1/20 0.66
TUBB P07437 1/20 0.66
TUBA3C P0DPH7 1/20 0.66
GAA P10253 1/20 0.66
MAPT P10636 1/20 0.66
HPGD P15428 1/20 0.66
ALOX15 P16050 1/20 0.66
MAPK1 P28482 1/20 0.66
HTT P42858 1/20 0.66
TUBA1B P68363 1/20 0.66
TUBA4A P68366 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335346 0.86 MYB (1.00) MYB
SCHEMBL4320678 0.85 HSD17B10 (0.71) MYBMEN1KMT2AALDH1A1PKM
SCHEMBL4327922 0.85 MYB (0.83) MYB
SCHEMBL8543671 0.84 MYB (1.00) MYBMEN1KMT2ALMNAMAPT
SCHEMBL5618119 0.84 HSD17B10 (0.64) MYBMEN1KMT2AALDH1A1PKM
SCHEMBL8544205 0.83 CYP1A2 (0.73) MYBMEN1KMT2AALDH1A1HSD17B10
SCHEMBL5044963 0.83 MYB (0.89) MYB
SCHEMBL4320586 0.82 MEN1 (0.82) MEN1KMT2AALDH1A1PKMHSD17B10
SCHEMBL4331540 0.82 MYB (0.87) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL12136727 0.81 MYB (0.75) MYB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1230232-B1 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2004-02-25 EP claimed
US-7507762-B2 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2009-03-24 US disclosed
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-07-14 US disclosed
US-6906203-B1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-06-14 US disclosed
EP-1230232-B1 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2004-02-25 EP disclosed
EP-1230232-A2 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2002-08-14 EP disclosed
WO-2001034591-A2 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, CASP5 MYB 429/4885MEN1 2868/4885KMT2A 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.